Thermo Fisher (TMO) on Solana

Bernstein resumed coverage of Thermo Fisher Scientific (TMO) on June 26 with a Market Perform rating and a $520 price target, citing broad improvement across the life science tools and diagnostics sector. The firm pointed to a pickup in new drug approvals, growth in clinical trial starts, and stronger biotech funding as early signals that customer spending is beginning to recover.

Looking further out, Bernstein flagged re-shoring initiatives and rising AI-driven demand for semiconductor-related tools as additional tailwinds that could support investment in Thermo Fisher's product lines. The resumption contrasts somewhat with Piper Sandler's cautious June 11 initiation at Neutral and a $510 price target, suggesting analysts broadly agree the sector is stabilizing but differ on the pace of upside.

Thermo Fisher Scientific (TMO) is trading around $505 per share—down roughly 14.6% year-to-date despite a 12-month gain of 23.2% and a recent eight-week bounce of nearly 13%. A Simply Wall St analysis flags conflicting valuation signals: the stock's P/E of 27.45x sits well below the life sciences industry average of 36.37x and the broader peer-group average of 42.26x, yet it trades marginally above the firm's customized fair-value P/E benchmark of 25.68x, putting it in an ambiguous zone. A discounted cash flow model using trailing free cash flow of $6.79 billion and a projected 2030 figure of $11.45 billion produces an intrinsic value of $577.18—implying the shares are roughly 12% cheap on a cash-flow basis.

The divergence between the P/E and DCF readings reflects ongoing uncertainty around large life-sciences suppliers as investors weigh pharmaceutical and biotech customer demand alongside broader macro pressures. Simply Wall St scores TMO at 3 out of 6 on its valuation checklist, summarizing the mixed picture as neither clearly overvalued nor a screaming bargain at current levels.